The LATA trial will find out if taking a long-acting injectable form of HIV medicines, called
cabotegravir and rilpivirine, every 2 month works as well as taking tablet HIV medicines
every day in young people aged 12-19 years of age.
The trial is organised by an international group of researchers from Europe and Africa, and
will include 460 young people, from Kenya, South Africa, Uganda and Zimbabwe.
Phase:
Phase 3
Details
Lead Sponsor:
University College, London
Collaborators:
Africa Health Research Institute Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands. European and Developing Countries Clinical Trials Partnership (EDCTP) Janssen-Cilag Ltd. London School of Hygiene and Tropical Medicine MRC/UVRI and LSHTM Uganda Research Unit PENTA Foundation University of York ViiV Healthcare